American Heart Journal
Volume 152, Issue 1 , Pages 94-101 , July 2006

Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure

Received 6 May 2005 ,Accepted 21 September 2005.

References 

  1. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351:9–13
  2. Hobbs FD, Davis RC, Roalfe AK, et al. Reliability of N-terminal pro–brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002;324:1498–1500
  3. Ng LL, Loke I, Davies JE. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail. 2003;5:775–782
  4. Ng LL, Loke I, Davies JE, et al. Community screening for heart failure using plasma and urinary natriuretic peptides. J Am Coll Cardiol. 2005;45:1043–1050
  5. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and dysfunction. JAMA. 2002;288:1252–1259
  6. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non–ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  7. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  8. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med. 1997;336:973–979
  9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med. 2000;342:836–843
  10. Vasan RS, Sullivan LM, Roubenoff R, et al. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly patients without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491
  11. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938
  12. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–2142
  13. Askari AT, Brennan ML, Zhou X, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615–624
  14. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367
  15. Omland T, Persson A, Ng L, et al. N-terminal pro–B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913–2918
  16. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–1379
  17. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika. 1991;78:3
  18. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43:1019–1026
  19. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–1842

PII: S0002-8703(05)00876-8

doi: 10.1016/j.ahj.2005.09.020

American Heart Journal
Volume 152, Issue 1 , Pages 94-101 , July 2006

Article Tools

* Image Usage & Resolution